## PATENT COOPERATION TREATY

# PCT

REC'D	28	FEB	2005

**WIPO** 

PCT

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PPD 70229MO	FOR FURTHER ACTION	See Form PCT/IPEA/416			
International application No. PCT/GB2004/000726	International filing date (day/month/year) 23.02.2004	Priority date (day/month/year) 24.02.2003			
International Patent Classification (IPC) or nat C07C253/30, C07C255/39	ional classification and IPC				
Applicant SYNGENTA LIMITED					
1	The applicant according to Alt	by this International Preliminary Examining icle 36.			
2. This REPORT consists of a total of 5 sheets, including this cover sheet.					
3. This report is also accompanied by ANNEXES, comprising:					
a. U sent to the applicant and to t	he International Bureau) a total of she	eets, as follows:			
sheets of the description and/or sheets containing Administrative Instruction	, claims and/or drawings which have be rectifications authorized by this Author ns).	een amended and are the basis of this report rity (see Rule 70.16 and Section 607 of the			
☐ sheets which supersede beyond the disclosure in Supplemental Box.	earlier sheets, but which this Authority the international application as filed, as	considers contain an amendment that goes s indicated in item 4 of Box No. I and the			
b.   (sent to the International Burnsequence listing and/or tables  Box Relating to Sequence List	eau only) a total of (indicate type and no related thereto, in computer readable sting (see Section 802 of the Administra	number of electronic carrier(s)) , containing a form only, as indicated in the Supplemental ative Instructions).			
4. This report contains indications relat	ing to the following items:				
☑ Box No. I Basis of the opinio.					
☐ Box No. II Priority	11				
	of opinion with respect to a contract				
	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  Lack of unity of invention				
☑ Box No. V Reasoned stateme	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Box No. VI Certain documents	Certain documents cited				
☐ Box No. VII Certain defects in t	Certain defects in the international application				
☐ Box No. VIII Certain observation					
Date of submission of the demand					
and a comment of the definition	Date of completion	of this report			
22.09.2004	01.03.2005				
Name and mailing address of the international preliminary examining authority:	Authorized Officer	and Petro.			
European Patent Office - P.B. 581 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 Fax: +31 70 340 - 3016	<b></b> , , , , ,	70 340-4359			

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/000726

-	Box No. I	Basis of the report
1	. With regar	rd to the <b>language</b> , this report is based on the international application in the language in which it was otherwise indicated under this item.
	☐ inte	eport is based on translations from the original language into the following language, is the language of a translation furnished for the purposes of: ernational search (under Rules 12.3 and 23.1(b)) blication of the international application (under Rule 12.4) ernational preliminary examination (under Rules 55.2 and/or 55.3)
2	. With regard have been	d to the <b>elements*</b> of the international application, this report is based on (replacement sheets which furnished to the receiving Office in response to an invitation under Article 14 are referred to in this originally filed" and are not annexed to this report):
	Description	ı, Pages
	1-10	as originally filed
	Claims, Nur	nbers
	1-8	as originally filed
	□ a sequ	ence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3.	☐ the ☐ the ☐ the ☐ the ☐	nendments have resulted in the cancellation of: description, pages claims, Nos. drawings, sheets/figs sequence listing (specify): table(s) related to sequence listing (specify):
	Supplement  the c  the c  the c  the c	cort has been established as if (some of) the amendments annexed to this report and listed below in made, since they have been considered to go beyond the disclosure as filed, as indicated in the description, pages claims, Nos.  Idrawings, sheets/figs requence listing (specify): table(s) related to sequence listing (specify):
	* If ite	m 4 applies, some or all of these sheets may be marked "superseded."

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/000726

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Inventive step (IS)

Yes: Claims

1-8

No: Claims

Yes: Claims

No: Claims

Industrial applicability (IA)

Yes: Claims

1-8 1-8

No: Claims

. .

2. Citations and explanations (Rule 70.7):

see separate sheet

#### Re Item V.

The following documents are referred to in this communication:

D1: EP 0 304 954 A (ICI AUSTRALIA LTD) 1 March 1989 (1989-03-01)

D2: WO 02/06202 A (SYNGENTA LTD ;BROWN STEPHEN MARTIN (GB);

GOTT BRIAN DAVID (GB)) 24 January 2002 (2002-01-24)

D3: EP 0 109 681 A (SHELL OIL CO) 30 May 1984 (1984-05-30)

### 1 Novelty:

The subject-matter of claims 1-8 is considered as new in the sense of Article 33(2) PCT, because the available prior art documents do not disclose a process as defined in these claims.

### 2 Inventive step:

## 2.1 INDEPENDENT CLAIM 1

The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claim 1 is not inventive in the sense of Article 33(3) PCT over either of documents D1-D3.

Document D1 discloses (cp. example 19) a process for the preparation of gamma-cyhalothrin (IV) wherein 1R cis-Z 3-(2-chloro-3,3,3-trifluoro-1-propenyl)-2,2-dimethylcyclopropanecarboxylic acid (I) is condensed with the (S)-cyanohydrin of 3-phenoxy benzaldehyde (III) in the presence of dicyclohexylcarbodiimide. The difference between the subject-matter of claim 1 of the application and example 19 of D1 is that in claim 1 acid (I) is converted into the corresponding acid chloride (II) which is then reacted with alcohol (III) to give the desired gamma-cyhalothrin (IV), whereas in example 19 of D1 acid (I) is directly treated with alcohol (III) to give (IV).

The problem underlying the application is considered as the provision of a further process for the preparation of gamma-cyhalothrin.

The problem is solved by converting (I) into the corresponding acid chloride (II) which is then reacted with (III) to give gamma-cyhalothrin (IV).

D1 also teaches (cp. p.21, I.22-30) that the pyrethroids can be prepared not only by condensation of the acid with the (S)-cyanohydrin of 3-phenoxy benzaldehyde (III), but also discloses the option of performing the esterification by treatment of the (S)-cyanohydrin of 3-phenoxy benzaldehyde (III) with the acid halide. Thus, in view of the teachings of D1, the subject-matter of claim 1 is considered as obvious. Consequently, the subject-matter of claim 1 does not involve an inventive step over D1.

Document D2 discloses (cp. p.3, scheme; claims 5 and 6; example 12) a process for preparing enantiopure pyrethroid esters by converting a single enantiomer of an acid into the corresponding acid chloride which is then reacted with the cyanohydrin of 3-phenoxy benzaldehyde to give the desired product.

The general formula of the acid and the acid chloride of D2 encompass the acid and the acid chloride of claim 1 of the application.

Thus, in view of the teachings of D2 the subject-matter of claim 1 is considered as obvious. Consequently, the subject-matter of claim 1 does not involve an inventive step over D2.

Document D3 discloses (cp. claims 7 and 10) a process for preparing pyrethroid esters by treating a chiral cyclopropane carboxylic acid chloride with the (S)-cyanohydrin of 3-phenoxy benzaldehyde (III).

2,2-Dimethyl-3-(2-(trifluoromethyl)-2-chlorovinyl)cyclopropanecarbonyl chloride is disclosed (cp. p.21, I.19-20) as a preferred starting material.

Thus, in view of the teachings of D3 the subject-matter of claim 1 is considered as obvious. Consequently, the subject-matter of claim 1 does not involve an inventive step over D3.

### 2.2 DEPENDENT CLAIMS 2-8

Dependent claims 2-8 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of novelty and/or inventive step (Article 33(2) and (3) PCT).